Terms ending in 2032
Every in-force patent on Eyepoint, Inc.'s record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,333,173 | Bioerodible Silicon-Based Devices for Delivery of Therapeutic Agents In force · High confidence | Eyepoint, Inc. | In force | High confidence | |
| US 8,999,325 | Treatment of Ocular Disease In force · High confidence | Eyepoint, Inc. | In force | High confidence | |
| US 10,150,811 | Methods for Treating Vascular Leak Syndrome and Cancer In force · Medium confidence | Eyepoint, Inc. | In force | Medium confidence | |
| US 10,329,357 | Treatment of Ocular Disease In force · Medium confidence | Eyepoint, Inc. | In force | Medium confidence | |
| US 10,815,300 | Methods for Treating Vascular Leak Syndrome and Cancer In force · Medium confidence | Eyepoint, Inc. | In force | Medium confidence | |
| US 12,043,664 | Methods for Treating Vascular Leak Syndrome and Cancer In force · Medium confidence | Eyepoint, Inc. | In force | Medium confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.